Skip to search formSkip to main contentSkip to account menu

losmapimod

Known as: GW-856553X, GW856553X, 3-pyridinecarboxamide, 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylpropyl)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
2016
2016
Abstract 19771: Impact of Losmapimod on Cardiovascular Death and Heart Failure After ST-Elevation Myocardial Infarction in LATITUDE TIMI-60
Introduction: Inhibition of inflammation with the p38 MAP kinase inhibitor losmapimod may reduce adverse ventricular remodeling… 
2016
2016
Heart failure: Vagal nerve stimulation in chronic heart failure
Maladaptive processes after myocardial infarction (MI) might involve p38 mitogen-activated protein kinase (MAPK)-stimulated… 
Review
2015
Review
2015
Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome
An improved understanding of the pathogenesis of acute coronary syndromes and its relationship to atherosclerotic plaque rupture… 
2015
2015
Proliferation of the human urothelium is induced by atypical β1 -adrenoceptors.
We wanted to assess whether β-adrenoceptors mediate proliferation in the normal and malignant urothelial cell lines UROtsa and… 
2014
2014
A Low‐Frequency Variant in MAPK14 Provides Mechanistic Evidence of a Link With Myeloperoxidase: A Prognostic Cardiovascular Risk Marker
BACKGROUND Genetics can be used to predict drug effects and generate hypotheses around alternative indications. To support… 
2014
2014
Acute coronary syndromes: Promising data for losmapimod in NSTEMI
Promising data for losmapimod in NSTEMI A novel p38 mitogen-activated protein kinase (MAPK) inhibitor, losmapimod, has been shown… 
Review
2013
Review
2013
[Losmapimod: a novel drug against cardiovascular diseases?].
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an… 
2013
2013
Single doses of p 38 MAP kinase inhibitors or prednisolone affect CRP and IL-6 in patients with active Rheumatoid Arthritis ( RA )
Purpose: To investigate the effects of single doses of losmapimod, dilmapimod (inhibitors of p38 MAPK) and prednisolone on… 
2010
2010
In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical study.
OBJECTIVES The aim of the present study was to determine the in vivo efficacy of p38 mitogen-activated protein kinase (MAPK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)